What Is a Complete Response Letter?
A Complete Response Letter, or CRL, is a letter from the FDA stating that a drug application cannot be approved in its current form.
A CRL does not always mean the drug is dead. But it means the FDA is not approving the application yet.
Simple definition
A Complete Response Letter is the FDA’s formal rejection of an NDA or BLA in its current form. The FDA may request additional clinical data, another trial, longer follow-up, manufacturing fixes, facility reinspection, safety analysis, labeling changes, statistical clarification, dose optimization or risk mitigation plans.
Why CRLs matter
Biotech stocks often trade around expected approval. If the market expects approval and the FDA issues a CRL, the stock can fall sharply.
Types of CRL problems
Clinical efficacy issues are often the most serious because they may require another pivotal trial. Safety issues can be difficult if the disease setting has alternatives. Manufacturing issues can sometimes be fixed faster but can still delay approval. Labeling issues may reduce commercial value.
CRL vs approval delay
Not every delay is a CRL. Sometimes the FDA extends the review timeline or asks for more information before the action date. A CRL is a formal decision that the application is not ready for approval.
Read more: What Is a PDUFA Date?
Can a company recover from a CRL?
Yes, but it depends on the issue. A fixable manufacturing CRL may be resolved in months. A CRL requiring another Phase 3 trial may take years and require significant financing.
Investor checklist after a CRL
Ask whether the issue was clinical, safety, manufacturing or labeling, whether FDA requested another trial, how long resubmission could take, whether the company has enough cash, whether dilution will be needed and whether the drug is still commercially viable.
Read more: What Is Dilution in Biotech Stocks?
Frequently asked questions
What is a Complete Response Letter (CRL)?
A Complete Response Letter is a letter from the FDA stating that a drug application cannot be approved in its current form. It is the FDA’s formal decision not to approve an NDA or BLA yet. A CRL may request additional clinical data, another trial, longer follow-up, manufacturing fixes, a facility reinspection, labeling changes or dose optimization.
Does a CRL mean the drug is dead?
Not necessarily. A CRL means the application is not approvable as submitted, but the outcome depends on the issue. A fixable manufacturing problem may be resolved in months, while a CRL requiring another Phase 3 trial can take years and significant financing. It changes the risk profile immediately, but it is not always fatal.
What is the difference between a CRL and a review delay?
A review delay is when the FDA extends the review timeline or asks for more information before the action date, and the application is still under review. A CRL is a formal decision that the application cannot be approved in its current form. A delay keeps the process open; a CRL ends the current review cycle until the company resubmits.
Bottom line
A CRL means the FDA has declined to approve the drug in its current form. It is not always fatal, but it changes the risk profile immediately. Is the CRL fixable, and at what cost in time, money and dilution?